Opinion of the Governing Board of the Innovative Medicines Initiative 2 Joint Undertaking on the IMI2 JU Final Annual Accounts 2015

THE GOVERNING BOARD OF THE INNOVATIVE MEDICINES INITIATIVE 2 JOINT UNDERTAKING (IMI2 JU),

Having regard to the Statutes annexed to the Council Regulation (EU) No 557/2014 of 6 May 2014 establishing the Innovative Medicines Initiative 2 Joint Undertaking and in particular Articles 7.3 (i), 9.4 (d) and 17.3 paragraph 4 thereof;

Having regard to the Financial Rules of the Innovative Medicines Initiative 2 Joint Undertaking adopted by the Governing Board on 22 December 2015 (IMI2-GB-DEC-2015-44) and in particular Article 43 paragraph 2 thereof;

Whereas

1. IMI2 JU has concluded a Service level agreement with Directorate General for Budget for the provision of accounting services from 1st September 2015;
2. The Directorate General for Budget in its function of IMI2 JU Accounting Officer has prepared and submitted to the European Court of Auditors and to the European Commission the Provisional Annual Accounts 2015;
3. The European Court of Auditors has scrutinised the Provisional Accounts and has formulated recommendations that have all been taken into account in the preparation of the Final Accounts of the IMI2 JU;
4. The Accounting Officer has adjusted the liabilities part of the accounts as agreed with the Court of Auditors and has introduced notes to the final accounts highlighting the updating of estimations made in January 2016 with the actual information reported by IMI1 members and the additional amounts of validated IMI1 and IMI2 in kind contributions.
5. The Final Accounts follow standard Commission accounting policies and harmonized standard template;

Formulates a positive opinion on the annexed Final Annual Accounts 2015 including the Report on budgetary and financial management.

Requests to the Directorate General for Budget in its function of IMI2 JU Accounting Officer to further reflect specificities in future Final Accounts for 2016, including the breakdown of the IMI1 and the IMI2 programmes as requested by the European Parliament through the Discharge procedure 2014 and consider including the reconciliation of Budget outturn with Economic outturn accounts.

Brussels, on 18/7/16

For the Governing Board of the Innovative Medicines Initiative 2 JU

Marc de Garidel
Chair of the IMI2 JU Governing Board

Annex: IMI2 JU Final Annual Accounts 2015

IMI2/INT/2016-01909